Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GRI

Sanofi reception

FDA approves Sanofi’s follow-on version of Lilly’s Humalog

French pharma firm hopes Admelog will make a significant commercial impact in 2018

- PMLiVE

Novo Nordisk gets FDA nod for once-weekly rival to Lilly’s Trulicity

GLP-1 agonist Ozempic approved in the US for type 2 diabetes

Sanofi reception

Dupixent dulls pain of diabetes slump at Sanofi

Biosimilar competition caused steep declines in its flagship product Lantus

- PMLiVE

Dexcom and Fitbit team up to tackle diabetes management

Will develop a wearable blood glucose tracking product

- PMLiVE

AZ gets US green light for new Bydureon formulation

Its latest injectable suspension proven to reduce blood sugar levels

- PMLiVE

J&J seeks US OK to add CV claim to Invokana label

If approved the treatment could better compete with rivals Jardiance and Victoza

- PMLiVE

Novo’s semaglutide beats Lilly’s Trulicity in diabetes contest

Analysts predict the drug could be worth $8.7bn in the next five years

- PMLiVE

Type 2 diabetes market set to soar to $64bn by 2026

Rising prevalence, progressive nature and diagnosis of the condition behind the surge

- PMLiVE

Novo Nordisk bolsters management team

Appoints Camilla Sylvest and Doug Langa

- PMLiVE

Novo launches personalised diabetes management mobile app

Partners with Glooko on app that syncs blood glucose and activity data

Roche acquires digital diabetes management platform

Will integrate mySugr within its new patient-centred health services arm

- PMLiVE

FDA panel backs CV claims for Novo Nordisk’s Victoza

LEADER trial shows the diabetes treatment reduces risk of cardiovascular death by 13%

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links